Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedAppFRA:WQ1 -4.17%43 Return-on-Tangible-Equity is 520.31% as of Jun. 2026, which is 3373% above its 10-year median of 14.98. GuruFocus rates FRA:WQ1 with a GF Score™ of 43/100 and a GF Value™ of €0.04. The stock has 6 warning signs investors should review. Among 586 Healthcare Providers & Services companies, MedApp ranks better than 99.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MedApp's annualized net income for the quarter that ended in Jun. 2026 was €1.01 Mil. MedApp's average shareholder tangible equity for the quarter that ended in Jun. 2026 was €0.19 Mil. Therefore, MedApp's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 520.31%.
The historical rank and industry rank for MedApp's Return-on-Tangible-Equity or its related term are showing as below:
FRA:WQ1'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -113.38 Med: 14.98 Max: 35.54
Current: Negative Tangible Equity
During the past 13 years, MedApp's highest Return-on-Tangible-Equity was 35.54%. The lowest was -113.38%. And the median was 14.98%.
FRA:WQ1's Return-on-Tangible-Equity is ranked better than 99.83% of 586
companies
in the Healthcare Providers & Services industry
Industry Median: 10.74
vs FRA:WQ1: Negative Tangible Equity
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MedApp Return-on-Tangible-Equity Related Terms
MedApp Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MedApp's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:WQ1 vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, MedApp's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedApp Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedApp's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MedApp's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 520.31% mean?
MedApp (FRA:WQ1) has a Return-on-Tangible-Equity of 520.31% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MedApp and its competitors. This is 3373% above median its historical median of 14.98. According to the industry distribution chart, MedApp ranks #1 out of 586 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is MedApp's Return-on-Tangible-Equity too high?
MedApp's current Return-on-Tangible-Equity of 520.31% is 3373% above median its 10-year median of 14.98. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.74. MedApp's value of 520.31% is 4744.6% above this industry median. Based on the distribution chart, MedApp ranks #1 out of 586 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MedApp has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does MedApp's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedApp ranks #1 out of 586 companies for Return-on-Tangible-Equity. This places MedApp in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.74. MedApp's value of 520.31% is 4744.6% above this benchmark. While the company's 10-year median is 14.98 vs. the industry median of 10.74, MedApp has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.74, based on 586 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedApp's current Return-on-Tangible-Equity of 520.31% is 4744.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MedApp and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedApp's current Return-on-Tangible-Equity is 520.31%, which is 3373% above median its own 10-year median of 14.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedApp stock overvalued right now?
MedApp (FRA:WQ1) has a current Return-on-Tangible-Equity of 520.31%. The stock's GF Value™ is €0.04, compared to a current price of €0.02 — trading 42.5% below its estimated fair value. The current Return-on-Tangible-Equity is 520.31%, which is 3373% above median its 10-year median of 14.98 and 4744.6% above the Healthcare Providers & Services industry median of 10.74. MedApp's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MedApp (FRA:WQ1), the current Return-on-Tangible-Equity is 520.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedApp (FRA:WQ1) Overvalued in 2026?
Based on GuruFocus' analysis, MedApp stock appears to be undervalued.
The current stock price of €0.02 is trading 42.5% below its estimated GF Value™ of €0.04.
Key valuation signals for FRA:WQ1:
Return-on-Tangible-Equity: 520.31% (3373% above median its 10-year median of 14.98)
GF Value™: €0.04 vs. price of €0.02 (42.5% below fair value)
Industry Position: 4744.6% above the Healthcare Providers & Services median (#1 of 586)
No single metric tells the full story. See the FRA:WQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WQ1 has been successfully added to your 
